Zenith Drugs Limited Submits Revised Financial Results Following Tax Classification Correction

Zenith Drugs Limited Submits Revised Financial Results Following Tax Classification Correction​

Zenith Drugs Limited, a company previously known as Zenith Drugs Private Limited, has submitted revised financial results for the half year and the full year ended March 31, 2026. This submission involves correcting an inadvertent classification error in its previous filing.

The clarification pertains to the provision for current income tax. The original financial statement had allocated a provision of Rs 160.40 Lakhs in the Balance Sheet to "Reserves & Surplus," when it should have been classified under "Current Tax Liability / Provision for Taxation." Zenith Drugs Limited clarified that this error was unintentional and confirmed that the correction did not impact the underlying profits or financial results for the half year and the full year ended March 31, 2026.

Financial Performance Highlights (Half Year Ended March 31, 2026)​

The company's Statement of Profit & Loss shows key metrics across both the half-yearly and annual periods. For the nine months ended March 31, 2026, Total Revenue stood at 9,618.30 Lakhs, up from 7,822.35 Lakhs in the corresponding period of the previous year.

Key figures across all reported periods are detailed below:

Balance Sheet and Financial Position​

As of March 31, 2026, Zenith Drugs Limited reported total equity and liabilities amounting to 18,751.97 Lakhs, compared to 16,147.72 Lakhs as of the previous year. The company's shareholder funds included Share Capital of 1,714.88 Lakhs and Reserves and Surplus of 5,617.30 Lakhs.

The long-term debt obligations increased to 2,011.47 Lakhs from 1,279.55 Lakhs in the previous fiscal year. Current liabilities included a total of 189.97 Lakhs for other current liabilities, alongside short-term borrowings and trade payables totaling at 3,499.05 Lakhs and 5,558.89 Lakhs, respectively.

Cash Flow Summary​

The company's cash flow statement highlights trends in operational efficiency and investment activity across the two reporting years.


The company reported a net increase/decrease in cash of (610.00) Lakhs as at March 31, 2026, with the closing balance standing at 26.30 Lakhs.

ZENITHDRUG Stock Price Movement​

Zenith Drugs Limited shares today slipped by 2.73%, settling at ₹42.7 after closing in the post-market session. The stock traded within a tight range, hitting a low of ₹42.7 and seeing a volume of 4800 shares.